Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Exchange Rate Effect (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Exchange Rate Effect for 9 consecutive years, with -$1.9 million as the latest value for Q1 2026.

  • For Q1 2026, Exchange Rate Effect fell 515.38% year-over-year to -$1.9 million; the TTM value through Mar 2026 reached -$1.6 million, down 946.32%, while the annual FY2025 figure was $804000.0, 215.85% up from the prior year.
  • Exchange Rate Effect hit -$1.9 million in Q1 2026 for Bicycle Therapeutics, down from -$222000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $3.6 million in Q4 2022 and bottomed at -$2.6 million in Q3 2022.
  • Average Exchange Rate Effect over 5 years is -$94588.2, with a median of -$222000.0 recorded in 2025.
  • On a YoY basis, Exchange Rate Effect climbed as much as 59333.33% in 2022 and fell as far as 743.1% in 2022.
  • Bicycle Therapeutics' Exchange Rate Effect stood at $3.6 million in 2022, then plummeted by 63.73% to $1.3 million in 2023, then tumbled by 238.17% to -$1.8 million in 2024, then skyrocketed by 87.54% to -$222000.0 in 2025, then crashed by 775.68% to -$1.9 million in 2026.
  • According to Business Quant data, Exchange Rate Effect over the past three periods came in at -$1.9 million, -$222000.0, and -$1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.